Stem Point Capital LP Pyxis Oncology, Inc. Call Options Transaction History
Stem Point Capital LP
- $378 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PYXS
# of Institutions
76Shares Held
23.5MCall Options Held
88.6KPut Options Held
47K-
Deep Track Capital, LP Greenwich, CT4.18MShares$12.1 Million0.59% of portfolio
-
Laurion Capital Management LP New York, NY3.86MShares$11.2 Million0.14% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.59MShares$7.52 Million0.02% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.66MShares$4.82 Million0.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$4.06 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $102M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...